← FDA DRUG APPROVALS

FDA ANDA · ANDA078930

BETAMETHASONE DIPROPIONATE

Sponsor: GLENMARK PHARMS

APPLICATION
ANDA078930
TYPE
ANDA
ORIGINAL APPROVAL
2008-09-23
LATEST ACTION
2020-07-07
ROUTE
TOPICAL
DOSAGE FORM
CREAM, AUGMENTED
MARKETING STATUS
Discontinued

Products

BETAMETHASONE DIPROPIONATEDiscontinued
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · CREAM, AUGMENTED · TOPICAL

Approval history

2020-07-07Labeling · Supplement 7 · standardAP
2020-07-07Labeling · Supplement 8 · standardAP
2015-09-16Labeling · Supplement 6 · standardAP
2008-09-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →